跳至主要内容
临床试验/NCT07037927
NCT07037927招募中不适用

Minnesota Retaining Employment and Talent After Injury/Illness Network (RETAIN) Phase 3

Mayo Clinic2 个研究点 分布在 1 个国家目标入组 1,000 人开始时间: 2025年7月7日最近更新:

试验速览

阶段
不适用
状态
招募中
发起方
Mayo Clinic
入组人数
1,000
试验地点
2
主要终点
Workers to maintain employment

研究概览

简要总结

MN RETAIN Phase 3 is a non-randomized trial to evaluate the impact of RETAIN program expansion and services on workforce retention and reduction of future workplace disability in the state of MN. The program is funded by US Department of Education (DOE). There will be collaboration between partners to implement best practices in early intervention to support injured or ill employees in stay-at-work and return-to-work. MN RETAIN involves a partnership between Mayo Clinic and MN Department of Employment and Economic Development (DEED), and stakeholders throughout MN. MN DEED serves as the main recipient and administrator of the funding within the state with Mayo Clinic a subrecipients of the grant.

研究设计

研究类型
Interventional
分配方式
Na
干预模型
Single Group
主要目的
Other
盲法
None

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • > 18-years-old,
  • MN Resident,
  • Works or intends to work in MN,
  • Meets one of the following:
  • Employed at the time of enrollment (must be a W2 employee) OR,
  • Unemployed and in the workforce (looking for a job) referred by either:
  • Dislocated Worker (DW) Program,
  • Healthcare provider/care team managing work restrictions
  • Within 6 months of last day of work,
  • Meets one of the following:
  • Provider work restrictions of unable to work for at least 2 weeks
  • Per healthcare team anticipated to be unable to work for at least 2 weeks
  • Employer's inability to accommodate current work restrictions
  • Meets one of the following:
  • Diagnosis of a personal injury or illness that impacts employment (acute injury/illness or exacerbation of a chronic condition).
  • Surgery or procedure anticipated within the next 4-weeks that impacts employment
  • Documentation of work restrictions (i.e., written note/form documentation in electronic medical record prior to enrollment)

排除标准

  • Does not have the capacity to give appropriate informed consent,
  • Active workers' compensation claim relating to the qualifying injury or illness,
  • Pending application OR Receiving Social Security Disability Insurance (SSDI) or -Supplemental Security Income (SSI),
  • Self-Employed (i.e., 1099 worker)

结局指标

主要结局

Workers to maintain employment

时间窗: 6 month after enrollment

Of the individuals participating, the number who achieve or maintain competitive integrated employment at the end of the enrollment period.

次要结局

  • Engagement Statewide(3 years)

研究者

发起方
Mayo Clinic
申办方类型
Other
责任方
Principal Investigator
主要研究者

Laura E. Breeher

Principal Investigator

Mayo Clinic

研究点 (2)

Loading locations...

相似试验

招募中
不适用
A Prospective Randomized Phase III Trial of Maintenance Pemetrexed versus Observation in Patients with Recurrent or Metastatic Urothelial Carcinoma who completed first line platinum-based chemotherapy without disease progressioNeoplasms
KCT0004751Asan Medical Center156
进行中(未招募)
1 期
A Phase 3, Long-Term Extension Study to Evaluate the Safety and Efficacy of Imsidolimab (ANB019) in the Treatment of Adult Subjects with Generalized Pustular PsoriasisSubjects with generalized pustular psoriasisMedDRA version: 20.0Level: PTClassification code 10037575Term: Pustular psoriasisSystem Organ Class: 10040785 - Skin and subcutaneous tissue disorders
EUCTR2021-001448-90-FRAnaptysBio Inc.45
进行中(未招募)
1 期
A Phase 3, Long-Term Extension Study to Evaluate the Safety and Efficacy of Imsidolimab (ANB019) in the Treatment of Adult Subjects with Generalized Pustular PsoriasisSubjects with generalized pustular psoriasisMedDRA version: 20.0Level: PTClassification code 10037575Term: Pustular psoriasisSystem Organ Class: 10040785 - Skin and subcutaneous tissue disorders
EUCTR2021-001448-90-DEAnaptysBio Inc.45
进行中(未招募)
1 期
A Phase 3, Long-Term Extension Study to Evaluate the Safety and Efficacy of Imsidolimab (ANB019) in the Treatment of Adult Subjects with Generalized Pustular PsoriasisSubjects with generalized pustular psoriasisMedDRA version: 20.0Level: PTClassification code 10037575Term: Pustular psoriasisSystem Organ Class: 10040785 - Skin and subcutaneous tissue disorders
EUCTR2021-001448-90-ESAnaptysBio Inc.45
进行中(未招募)
不适用
Maintenance therapy in advanced Lung Cancer.Advanced non-small cell lung cancer
EUCTR2013-001237-41-NOorwegian University of Science and Technology